<DOC>
	<DOCNO>NCT01770509</DOCNO>
	<brief_summary>Ulcers low extremity , cause chronic venous insufficiency cellulitis common patient older 65 year cause significant morbidity . Natural Matrix Bio polymer Membrane ( NMBM ) novel topical cosmetic cream contain mix natural wax , sugar lipid . The aim study test whether Natural Matrix Bio polymer Membrane ( NMBM ) effective adjunctive therapy treatment venous stasis post-erysipelas leg ulcer .</brief_summary>
	<brief_title>The Effect Cosmetic Cream NMBM Leg Ulcers - Pilot Study</brief_title>
	<detailed_description>Ulcers low extremity , particularly patient older 65 year , common among population . Studies estimate prevalence current chronic leg ulcer approximately 1 % . The common cause ( approximately 80 % ) think chronic venous insufficiency disease . Recurrent cellulitis additional common cause . The ulcer cause significant morbidity negative impact patient ' quality life . The care chronic vascular ulcer place significant burden patient health care system . Additionally , nonhealing ulcer place patient much high risk lower extremity amputation . Natural Matrix Bio polymer Membrane ( NMBM ) novel topical cosmetic cream contain mix natural wax , sugar lipid . The aim study test whether Natural Matrix Bio polymer Membrane ( NMBM ) effective adjunctive therapy treatment venous stasis post-erysipelas leg ulcer .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<mesh_term>Skin Ulcer</mesh_term>
	<criteria>1 . Signed dated write Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) approve informed consent obtain subject accordance local regulation ; 2 . Male female subject , ≥18 ≤90 year age 3 . Patient venous predominantly venous leg ulcer ( anklebrachial index &gt; 0.8 ) 4 . Chronic venous insufficiency posterysipelas ulcer 5 . Ulcer size 5 170 sq cm , inclusive 6 . Ulcer present least one month 7. anklebrachial index &gt; 0.7 1 . Suffers diabetes mellitus HbA1c ≥ 8 % 2 . Albumin le 2 . 2 . Patients follow abnormal laboratory test level hemoglobin &lt; 10.5 g/dL platelet count &lt; 100 x 109/L serum albumin level &lt; 2.5 g/dL 3 . Suffers clinically significant arterial disease 34 . Has know allergy compound part protocol 45 . Has evidence ulcer / infection extend underlying muscle , tendon bone 56 . Has use investigational drug ( ) within 30 day precede randomization 67 . Is unable manage selftreatment 78 . Is pregnant , nurse mother woman child bear potential use adequate form contraception ( abstinence ) 8 . 9 . Suffers condition opinion Investigator would compromise safety subject / quality data 9 . 10 . Unwilling unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic venous leg ulcer</keyword>
	<keyword>Venous ulcer</keyword>
	<keyword>Stasis ulcer</keyword>
	<keyword>Varicose ulcer</keyword>
</DOC>